NCT01329549: Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) |
|
|
| Terminated | 1 | 2 | Japan | BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min | Boehringer Ingelheim | Ovarian Neoplasms | 10/12 | 10/12 | | |
NCT01314105: BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer |
|
|
| Completed | 1 | 19 | Europe | BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min | Boehringer Ingelheim | Ovarian Neoplasms, Peritoneal Neoplasms | 07/13 | 04/16 | | |
NCT02835833: Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors |
|
|
| Completed | 1 | 21 | US | Nintedanib, BIBF1120, Bevacizumab, Avastin | University of Alabama at Birmingham, Boehringer Ingelheim | Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma | 04/18 | 06/18 | | |
